Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02153944 · ClinicalTrials.gov registry record · Phase 4
Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety
A Phase 4 study of Anxiety Disorder, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 4
- Development phase
- 142
- Enrollment target
- 1
- Study location
NCT02153944: Completed Phase 4 study of Anxiety Disorder, sponsored by National Institute of Mental Health (NIMH).
NCT02153944 is a Phase 4 study of Anxiety Disorder that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 142 participants, below the 418-participant average among 20 other Anxiety Disorder trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02153944, a Phase 4 study of Anxiety Disorder, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective: The overall aim of this protocol is to examine the effect of pharmacological manipulations of affective and cognitive processes on anxiety and task performance. Ultimately, the goal is 1) to provide insight into the relative influence of cognitive and affective states on anxiety, 2) generate theoretical models that can be applied to a better understanding of the interaction between cognition and emotion, 3) develop a better screening approach to candidate anxiolytics, and 4) help formulate novel therapeutic interventions for clinical anxiety. Excessive or inappropriately sustained anxiety and fear lead to the most common group of psychiatric disorders. A number of theoretical models have been proposed to understand the mechanisms engaged in these maladaptive behaviors. Most recent emphasis has focused on the synergistic contribution of cognitive and emotional processes. Our laboratory has been instrumental in delineating aspects of behavioral and neural processes that are associated with fear and anxiety, using psychophysiological and neuroimaging measures of fear and anxiety. Evidence shows that levels of anxiety modulate cognitive performance, such as working memory or perceptual discrimination, and that, conversely, cognitive engagement influences severity of experimentally induced anxiety. The exact contribution of emotional processes vs. cognitive processes to the experience of anxiety is not clear, similarly to the neural mechanisms underlying these interactions. In this protocol, we propose to manipulate pharmacologically separately cognitive and emotional processes to dissociate their contribution to fear/anxiety, while using state-of-the-art measures of anxiety derived from translational work. Indeed, we already developed integrative experimental models of fear and anxiety via the manipulation of predictable and unpredictable shock, respectively. We already employed successfully these models to measure anxiolytic and anxiogenic effects of vari
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Methylphenidate
- DRUG Propranolol
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2014-06-16 |
| Est. Completion | 2021-10-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02153944
The ClinicalTrials.gov registry entry for NCT02153944 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 418-participant average among 20 other Anxiety Disorder trials with a reported enrollment target (66% lower). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anxiety Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02153944 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02153944 about?
NCT02153944 is a clinical study titled "Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety". Objective: The overall aim of this protocol is to examine the effect of pharmacological manipulations of affective and cognitive processes on anxiety and task performance. Ultimately, the goal is 1) to provide insight into the relative influence of cognitive and affective states on anxiety, 2) gene...
What is the current status of trial NCT02153944?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 142 participants. The study started on 2014-06-16. Estimated completion is 2021-10-07.
What conditions does trial NCT02153944 study?
This clinical trial studies the following conditions: Anxiety Disorder.
What interventions are being tested in trial NCT02153944?
The interventions under investigation include: Placebo (DRUG), Methylphenidate (DRUG), Propranolol (DRUG).
Who is sponsoring clinical trial NCT02153944?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02153944 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder
COMPLETED · Phase 4
-
Ketamine Infusion for Adolescent Depression and Anxiety
COMPLETED · Phase 4
-
Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study
RECRUITING · NA
-
Low-Intensity Focused Ultrasound and the Complex Patient
RECRUITING · NA
-
Integrated CBT to Improve Functioning in Veterans With Anxiety and Substance Use
RECRUITING · NA
-
Unified Protocol: Community Connections
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.